Oct 28, 2025 04:30PM Akebia abandons broad Vafseo trial after FDA meeting disagreement

Aug 21, 2025 08:01AM Akebia expands Vafseo access through IRC's 230 dialysis centers

Aug 7, 2025 07:08AM Akebia Therapeutics (AKBA) Tops Q2 EPS by 2c

Jun 4, 2025 08:01AM Akebia Therapeutics (AKBA) Reports Publication of U.S. Patient Data from Global Phase 3 Clinical Program

Jun 4, 2025 06:15AM H.C. Wainwright Assumes Akebia Therapeutics (AKBA) at Buy

May 8, 2025 07:11AM Akebia Therapeutics (AKBA) Tops Q1 EPS by 8c

Apr 28, 2025 06:22AM Leerink Partners Starts Akebia Therapeutics (AKBA) at Outperform

Apr 4, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Apr 3, 2025 08:01AM Akebia Therapeutics (AKBA) Announces Positive Opinion of European Medicines Agency for XOANACYL

Apr 1, 2025 03:13AM Jefferies Starts Akebia Therapeutics (AKBA) at Buy

Mar 26, 2025 09:29AM Piper Sandler on Akebia Therapeutics (AKBA): 'Continue to Like the Setup; Remain Buyers'

Mar 19, 2025 04:01PM Akebia Therapeutics (AKBA) Announces Proposed Public Offering of Common Stock

Mar 17, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Mar 14, 2025 09:44AM Akebia Therapeutics (AKBA) PT Raised to $6, Piper Sandler 'Buyers on Weakness'

Mar 13, 2025 07:07AM Akebia Therapeutics (AKBA) Misses Q4 EPS by 3c

Jan 24, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Jan 15, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Jan 14, 2025 11:06AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Jan 13, 2025 08:06AM Akebia Therapeutics (AKBA) Announces Multiple Positive Business Updates

Nov 7, 2024 07:11AM Akebia Therapeutics (AKBA) Misses Q3 EPS by 4c

Oct 22, 2024 08:03AM Akebia Therapeutics (AKBA) Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo for Patients on Dialysis

Oct 11, 2024 06:37AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Oct 10, 2024 08:02AM Akebia Therapeutics (AKBA) Reports CMS Grants TDAPA Reimbursement for Vafseo beginning January 1, 2025

Oct 8, 2024 06:49AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Oct 7, 2024 08:05AM Akebia Therapeutics (AKBA) and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo for Patients on Dialysis

Sep 6, 2024 06:55AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Sep 5, 2024 08:05AM Akebia Therapeutics (AKBA) and U.S. Renal Care Initiate the VOICE Trial of Vafseo (vadadustat) for Patients on Dialysis

Sep 3, 2024 04:12PM Akebia Therapeutics (AKBA) Files $250M Mixed Shelf

Aug 12, 2024 06:13AM Akebia Therapeutics (AKBA) PT Raised to $7.50 at H.C. Wainwright

Aug 8, 2024 07:06AM Akebia Therapeutics (AKBA) Reports In-Line Q2 EPS

Jul 11, 2024 06:01AM Akebia Therapeutics (AKBA) Provides Update on Continued Momentum of Commercial Launch of Vafseo

Jun 24, 2024 08:59AM Akebia Therapeutics (AKBA) Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer